FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313574080> ?p ?o ?g. }

• W2313574080 endingPage "5084" @default.
• W2313574080 startingPage "5084" @default.
• W2313574080 abstract "Abstract BackgroundVorinostat, also known as suberoylanilide hydroxamic acid or SAHA, is a potent, small molecule, pan-inhibitor of histone deacetylase (HDAC) with excellent oral bioavailability, and is commercially approved for cutaneous T cell lymphoma. Pan HDAC inhibitors induce acetylation of histone tails, relaxing condensed chromatin for transcriptional regulation of specific genes and can also target non histone nuclear proteins. In pre-clinical studies of HER-2 overexpressing breast cancer cells, vorinostat(V) synergistically augmented the effects of trastuzumab(T) by downregulating Her-2, pAKT, pERK 1/2, reduced apoptosis by decreasing Bcl-2, Bcl-XL, XIAP and survivin levels, while inducing pro-apoptotic Bim and Bak. Therefore, we hypothesized that adding vorinostat to trastuzumab would reverse trastuzumab resistance in patients with HER-2 positive metastatic breast cancer.MethodsAn open label dose de-escalation schema for the initial portion of the trial was planned. V 200 mg bid continuous daily dosing with 6 mg/kg T every 21 days was administered. Eligible patients: HER-2 positive by IHC (3+) or FISH, subsequently centrally confirmed; measurable metastatic or chest wall disease; any number of prior therapies including endocrine, chemotherapy, prior treatment with T and/or lapatinib were allowed; evidence of progressive disease on prior T was required. The Phase II primary objective was response rate by RECIST criteria.ResultsMedian age - 54 (range 40-69); PS was 0 or 1; 6 patients - ER+; median number of prior therapies - 3 (range 2-6). Six patients were treated at the starting dose of 200 mg bid daily V combined with 6 mg/kg T every 21 days. There were no dose limiting adverse events at this dosing level, eliminating the need to de-escalate and this was determined to be the optimal Phase II dose. A total of 16 patients were enrolled. The most common AEs (all grades) were 62%-diarrhea, 37%-nausea, fatigue; 31%-anemia, anorexia, vomiting, elevated creatinine, hyperglycemia, hypokalemia; 25%-thrombocytopenia. Grade 3,4 toxicities were dyspnea(n=2) and thrombocytopenia(n=2). Of the 16 total enrolled, 10 were centrally confirmed to have HER-2 positive disease by the ECOG Pathology Coordinating Office, 5 were HER-2 negative and 1 had insufficient tissue. None of 11 patients with centrally confirmed HER-2 positive disease (or unknown) had an objective response. One of 5 patients with centrally confirmed HER-2 negative disease had an objective response.ConclusionsIn this heavily pre-treated population who had either relapsed or progressed during trastuzumab containing therapy (either alone or in combination with chemotherapy), we failed to confirm our hypothesis that adding the histone deacetylase inhibitor, vorinostat, could reverse trastuzumab resistance. Correlative studies including hyperacetylation status of PBMC, CTC enumeration and peripheral as well as tumor methylation are ongoing. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5084." @default.
• W2313574080 created "2016-06-24" @default.
• W2313574080 creator A5019035696 @default.
• W2313574080 creator A5025970989 @default.
• W2313574080 creator A5033216433 @default.
• W2313574080 creator A5049331116 @default.
• W2313574080 creator A5053128814 @default.
• W2313574080 creator A5066769011 @default.
• W2313574080 creator A5071532761 @default.
• W2313574080 creator A5078607513 @default.
• W2313574080 creator A5080151636 @default.
• W2313574080 creator A5085329460 @default.
• W2313574080 date "2009-12-01" @default.
• W2313574080 modified "2023-09-24" @default.
• W2313574080 title "A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group." @default.
• W2313574080 doi "https://doi.org/10.1158/0008-5472.sabcs-09-5084" @default.
• W2313574080 hasPublicationYear "2009" @default.
• W2313574080 type Work @default.
• W2313574080 sameAs 2313574080 @default.
• W2313574080 citedByCount "8" @default.
• W2313574080 countsByYear W23135740802012 @default.
• W2313574080 countsByYear W23135740802014 @default.
• W2313574080 countsByYear W23135740802016 @default.
• W2313574080 countsByYear W23135740802017 @default.
• W2313574080 countsByYear W23135740802022 @default.
• W2313574080 crossrefType "journal-article" @default.
• W2313574080 hasAuthorship W2313574080A5019035696 @default.
• W2313574080 hasAuthorship W2313574080A5025970989 @default.
• W2313574080 hasAuthorship W2313574080A5033216433 @default.
• W2313574080 hasAuthorship W2313574080A5049331116 @default.
• W2313574080 hasAuthorship W2313574080A5053128814 @default.
• W2313574080 hasAuthorship W2313574080A5066769011 @default.
• W2313574080 hasAuthorship W2313574080A5071532761 @default.
• W2313574080 hasAuthorship W2313574080A5078607513 @default.
• W2313574080 hasAuthorship W2313574080A5080151636 @default.
• W2313574080 hasAuthorship W2313574080A5085329460 @default.
• W2313574080 hasConcept C104317684 @default.
• W2313574080 hasConcept C121608353 @default.
• W2313574080 hasConcept C126322002 @default.
• W2313574080 hasConcept C143998085 @default.
• W2313574080 hasConcept C197934379 @default.
• W2313574080 hasConcept C2775930923 @default.
• W2313574080 hasConcept C2776202225 @default.
• W2313574080 hasConcept C2776262904 @default.
• W2313574080 hasConcept C2776694085 @default.
• W2313574080 hasConcept C2777329042 @default.
• W2313574080 hasConcept C2778305200 @default.
• W2313574080 hasConcept C2778375690 @default.
• W2313574080 hasConcept C2778822529 @default.
• W2313574080 hasConcept C2779786085 @default.
• W2313574080 hasConcept C2779984678 @default.
• W2313574080 hasConcept C502942594 @default.
• W2313574080 hasConcept C530470458 @default.
• W2313574080 hasConcept C55493867 @default.
• W2313574080 hasConcept C64927066 @default.
• W2313574080 hasConcept C71924100 @default.
• W2313574080 hasConcept C86803240 @default.
• W2313574080 hasConcept C98274493 @default.
• W2313574080 hasConceptScore W2313574080C104317684 @default.
• W2313574080 hasConceptScore W2313574080C121608353 @default.
• W2313574080 hasConceptScore W2313574080C126322002 @default.
• W2313574080 hasConceptScore W2313574080C143998085 @default.
• W2313574080 hasConceptScore W2313574080C197934379 @default.
• W2313574080 hasConceptScore W2313574080C2775930923 @default.
• W2313574080 hasConceptScore W2313574080C2776202225 @default.
• W2313574080 hasConceptScore W2313574080C2776262904 @default.
• W2313574080 hasConceptScore W2313574080C2776694085 @default.
• W2313574080 hasConceptScore W2313574080C2777329042 @default.
• W2313574080 hasConceptScore W2313574080C2778305200 @default.
• W2313574080 hasConceptScore W2313574080C2778375690 @default.
• W2313574080 hasConceptScore W2313574080C2778822529 @default.
• W2313574080 hasConceptScore W2313574080C2779786085 @default.
• W2313574080 hasConceptScore W2313574080C2779984678 @default.
• W2313574080 hasConceptScore W2313574080C502942594 @default.
• W2313574080 hasConceptScore W2313574080C530470458 @default.
• W2313574080 hasConceptScore W2313574080C55493867 @default.
• W2313574080 hasConceptScore W2313574080C64927066 @default.
• W2313574080 hasConceptScore W2313574080C71924100 @default.
• W2313574080 hasConceptScore W2313574080C86803240 @default.
• W2313574080 hasConceptScore W2313574080C98274493 @default.
• W2313574080 hasIssue "24_Supplement" @default.
• W2313574080 hasLocation W23135740801 @default.
• W2313574080 hasOpenAccess W2313574080 @default.
• W2313574080 hasPrimaryLocation W23135740801 @default.
• W2313574080 hasRelatedWork W2059573980 @default.
• W2313574080 hasRelatedWork W2092771806 @default.
• W2313574080 hasRelatedWork W2117342140 @default.
• W2313574080 hasRelatedWork W2158259365 @default.
• W2313574080 hasRelatedWork W2313574080 @default.
• W2313574080 hasRelatedWork W2517194109 @default.
• W2313574080 hasRelatedWork W2588964444 @default.
• W2313574080 hasRelatedWork W2783139623 @default.
• W2313574080 hasRelatedWork W2887246175 @default.
• W2313574080 hasRelatedWork W4244633258 @default.
• W2313574080 hasVolume "69" @default.
• W2313574080 isParatext "false" @default.
• W2313574080 isRetracted "false" @default.
• W2313574080 magId "2313574080" @default.

• next